<?xml version='1.0' encoding='utf-8'?>
<document id="24563430"><sentence text="The role of cefditoren in the treatment of lower community-acquired respiratory tract infections (LRTIs): from bacterial eradication to reduced lung inflammation and epithelial damage."><entity charOffset="12-22" id="DDI-PubMed.24563430.s1.e0" text="cefditoren" /></sentence><sentence text="Lower respiratory tract infections (LRTIs), including pneumonia and acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD), are among the most common diagnoses in both outpatient and inpatient settings" /><sentence text=" Due to the burden of LRTIs healthcare providers must adopt practices focused on improving outcomes with the aim to reduce treatment failure and antibiotic resistances" /><sentence text=" Moreover, the role of acute and chronic infection in the pathogenesis of COPD has received considerable attention, since chronic infection can contribute to airways inflammation and COPD progression" /><sentence text=" This review discusses the role of cefditoren for the treatment of LRTIs, compared with the definition of &quot;appropriate&quot; of the WHO as &quot;the cost-effective use of antimicrobials which maximizes clinical therapeutic effect while minimizing both drug-related toxicity and the development of antimicrobial resistance&quot;"><entity charOffset="35-45" id="DDI-PubMed.24563430.s5.e0" text="cefditoren" /></sentence><sentence text="" /><sentence text="Cefditoren appears to meet the definition of &quot;appropriate&quot; for the treatment of LRTIs"><entity charOffset="0-10" id="DDI-PubMed.24563430.s7.e0" text="Cefditoren" /></sentence><sentence text=" In fact, this molecule shows an adequate pharmacokinetic profile without the need for any adjustment also in aged patients with mild renal impairment or mild-to-moderate hepatic dysfunction" /><sentence text=" The low drug-drug interaction potential of cefditoren can be an advantage also in poly-treated patients"><entity charOffset="44-54" id="DDI-PubMed.24563430.s9.e0" text="cefditoren" /></sentence><sentence text=" The antimicrobial spectrum of cefditoren includes both Gram+ and Gram- bacteria, with high activity against Streptococcus pneumoniae, including drug-resistant strains, Haemophilus infuenzae and Moraxella chatarrhalis"><entity charOffset="31-41" id="DDI-PubMed.24563430.s10.e0" text="cefditoren" /></sentence><sentence text=" Last, recent findings suggested that cefditoren can be a valid alternative to levofloxacin in outpatients with acute exacerbation of COPD; in this setting a treatment with cefditoren showed to be associated with a significant reduction of some key inflammatory markers involved in epithelial damage, including KL-6 and IL-6"><entity charOffset="38-48" id="DDI-PubMed.24563430.s11.e0" text="cefditoren" /><entity charOffset="79-91" id="DDI-PubMed.24563430.s11.e1" text="levofloxacin" /><entity charOffset="173-183" id="DDI-PubMed.24563430.s11.e2" text="cefditoren" /><pair ddi="false" e1="DDI-PubMed.24563430.s11.e0" e2="DDI-PubMed.24563430.s11.e0" /><pair ddi="false" e1="DDI-PubMed.24563430.s11.e0" e2="DDI-PubMed.24563430.s11.e1" /><pair ddi="false" e1="DDI-PubMed.24563430.s11.e0" e2="DDI-PubMed.24563430.s11.e2" /><pair ddi="false" e1="DDI-PubMed.24563430.s11.e1" e2="DDI-PubMed.24563430.s11.e1" /><pair ddi="false" e1="DDI-PubMed.24563430.s11.e1" e2="DDI-PubMed.24563430.s11.e2" /></sentence><sentence text="" /></document>